RSS-Feed abonnieren
![](/products/assets/desktop/img/oa-logo.png)
DOI: 10.1055/s-0034-1368553
Remarks by the Board of the Study Group for Cervical Pathology and Colposcopy on the “Comments on the Publication of Munich Nomenclature III by the Cytology Coordination Conference” by A. Schneider and P. Hillemanns (Geburtsh Frauenheilk 2014; 74: 242–243)
Kommentar des Vorstands der „Arbeitsgemeinschaft für Zervixpathologie und Kolposkopie“ zum Beitrag „Stellungnahme zur Veröffentlichung der ‚Münchner Nomenklatur III‘ von der Koordinations-Konferenz Zytologie“ von A. Schneider und P. Hillemanns (Geburtsh Frauenheilk 2014; 74: 242–243)Publikationsverlauf
Publikationsdatum:
01. August 2014 (online)
![](https://www.thieme-connect.de/media/gebfra/201407/lookinside/thumbnails/10.1055-s-0034-1368553-1.jpg)
The authors A. Schneider and P. Hillemanns welcome the revision of the previous Munich II cytology nomenclature and its international harmonization. However, they criticize statements by the authors of Munich III about the contribution Munich III can make towards improving communications between doctors, avoiding unnecessary follow-up examinations and therapies, and reducing subsequent costs. The authors also denounce a lack of evidence and criticize basing recommendations on individual cytological diagnostic groups; they recommend that the Munich III Nomenclature be simplified in analogy to the Bethesda System (TBS). They ignored the importance of the revised cytological nomenclature of Munich III for colposcopic diagnosis and for interventional colposcopy of precancerous squamous and glandular cells of the cervix and vagina.